세포 치료 제조 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global cell therapy manufacturing market size is expected to reach USD 19.01 Billion in 2034 from USD 5.60 Billion in 2025, growing at a CAGR of 14.54% during 2026-2034.This market is developing rapidly as cell-based therapies progress from research programs toward broader clinical development and commercialization. Increasing investment in regenerative medicine, immunotherapy, and advanced biological treatments is creating demand for specialized manufacturing capabilities. Cell therapies often require highly controlled processes involving cell collection, expansion, modification, testing, storage, and distribution. Growing clinical pipelines are encouraging pharmaceutical companies and biotechnology firms to invest in manufacturing infrastructure, while specialized contract development and manufacturing organizations are expanding their capabilities.

Technological innovation is supporting improvements in scalability, automation, quality control, and manufacturing consistency. Closed-system processing, automated cell handling, advanced bioreactors, digital monitoring, and improved cryopreservation technologies are helping address production challenges. Manufacturers are also developing standardized workflows to reduce variability and improve efficiency. Increasing adoption of personalized therapies is creating demand for flexible manufacturing systems capable of processing patient-specific materials. Regulatory requirements surrounding identity, purity, potency, and traceability are also encouraging investment in advanced manufacturing and quality-management infrastructure.

Future prospects are closely linked to clinical success, regulatory approvals, manufacturing scalability, and cost reduction. Companies are expected to develop more automated and standardized platforms capable of supporting larger patient populations while maintaining product quality. Advances in gene editing and cell engineering could expand the range of therapies requiring specialized manufacturing. Greater use of decentralized and regional production models may also improve treatment logistics. As the pipeline of cell-based therapies continues developing, manufacturing infrastructure is expected to become increasingly important to the broader advanced-therapy ecosystem.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Therapy Type

• Allogeneic Cell Therapy
• Autologous Cell Therapy

By Technology Type

• Somatic Cell Technology
• Cell Immortalization Technology
• Viral Vector Technology
• Genome Editing Technology
• Cell Plasticity Technology
• 3D Technology

By Manufacturing Purpose

• Clinical
• Commercial
• Pre-clinical

By Application

• Musculoskeletal
• Cardiovascular
• Gastrointestinal
• Neurological
• Oncology
• Dermatology
• Others

COMPANIES PROFILED

• Lonza Group Ltd., Thermo Fisher Scientific Inc., Cytiva, Sartorius AG, WuXi AppTec Co., Ltd., Charles River Laboratories International, Inc., Catalent, Inc., Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, AGC Biologics, Boehringer Ingelheim, KBI Biopharma, Inc., Minaris Regenerative Medicine, Novartis AG, Miltenyi Biotec B.V. & Co. KG, MaxCyte, Inc., OriGen Biomedical, BioNTech SE, AstraZeneca PLC, Takara Bio Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL THERAPY MANUFACTURING MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. Allogeneic Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Autologous Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL THERAPY MANUFACTURING MARKET: BY TECHNOLOGY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology Type
• 5.2. Somatic Cell Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cell Immortalization Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Viral Vector Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Genome Editing Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Cell Plasticity Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. 3D Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL THERAPY MANUFACTURING MARKET: BY MANUFACTURING PURPOSE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Manufacturing Purpose
• 6.2. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Pre-clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CELL THERAPY MANUFACTURING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Application
• 7.2. Musculoskeletal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cardiovascular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Gastrointestinal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Neurological Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.7. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CELL THERAPY MANUFACTURING MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Therapy Type
  • 8.2.2 By Technology Type
  • 8.2.3 By Manufacturing Purpose
  • 8.2.4 By Application
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Therapy Type
  • 8.3.2 By Technology Type
  • 8.3.3 By Manufacturing Purpose
  • 8.3.4 By Application
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Therapy Type
  • 8.4.2 By Technology Type
  • 8.4.3 By Manufacturing Purpose
  • 8.4.4 By Application
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Therapy Type
  • 8.5.2 By Technology Type
  • 8.5.3 By Manufacturing Purpose
  • 8.5.4 By Application
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Therapy Type
  • 8.6.2 By Technology Type
  • 8.6.3 By Manufacturing Purpose
  • 8.6.4 By Application
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CELL THERAPY MANUFACTURING INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Lonza Group Ltd
  • 10.2.2 Thermo Fisher Scientific Inc
  • 10.2.3 Cytiva
  • 10.2.4 Sartorius AG
  • 10.2.5 WuXi AppTec Co.Ltd
  • 10.2.6 Charles River Laboratories InternationalInc
  • 10.2.7 CatalentInc
  • 10.2.8 Samsung Biologics Co.Ltd
  • 10.2.9 Fujifilm Diosynth Biotechnologies
  • 10.2.10 AGC Biologics
  • 10.2.11 Boehringer Ingelheim
  • 10.2.12 KBI BiopharmaInc
  • 10.2.13 Minaris Regenerative Medicine
  • 10.2.14 Novartis AG
  • 10.2.15 Miltenyi Biotec B.V. & Co. KG
  • 10.2.16 MaxCyteInc
  • 10.2.17 OriGen Biomedical
  • 10.2.18 BioNTech SE
  • 10.2.19 AstraZeneca PLC
  • 10.2.20 Takara Bio Inc